New antimicrobial frontiers

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 10, 2011, Pages 888-900

  Zucca, M ^a   Scutera, S ^b   Savoia, D ^a  

^a Faculty of Medicine S Luigi Gonzaga   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Antimicrobial peptides; Antivirulence factors; Bacterial targets; Inhibitors of adhesion; Inhibitors of colonization; Phage therapy; Toxin inhibitors

Indexed keywords

ALPHA DEFENSIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BACTERIOCIN; BETA DEFENSIN; CATHELICIDIN; CECROPIN; CECROPIN D; DALBAVANCIN; DEFENSIN; DERMASEPTIN; DERMASEPTIN S1; ENDOTOXIN; INDOLICIDIN; LANTIBIOTIC; MAGAININ 1; MAGAININ 2; MAGAININ A; MAGAININ DERIVATIVE; MELITTIN; MICROCIN B17; NISIN; NZ 2114; ORITAVANCIN; PEXIGANAN ACETATE; PLECTASIN; POLYPEPTIDE ANTIBIOTIC AGENT; TELAVANCIN; TEMPORIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; CLOSTRIDIUM DIFFICILE; DEVICE INFECTION; DIABETIC FOOT; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME ACTIVITY; FOOT ULCER; FROG; GENE CLUSTER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION CONTROL; MULTIPLE ORGAN FAILURE; NONHUMAN; SEPTIC SHOCK; SEXUALLY TRANSMITTED DISEASE; SKIN INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; BACTERIAL ADHESION; BACTERIOPHAGES; QUORUM SENSING; VIRULENCE FACTORS;

EID: 79961004151     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711796575498     Document Type: Article

References (174)

1. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis., 2009, 48(1), 1-12.
2. Fischbach, M.A.; Walsh, C.T. Antibiotics for emerging pathogens. Science, 2009, 325(5944), 1089-1093.
3. ECDC/EMEA JOINT TECHNICAL REPORT: The bacterial challenge: time to react. EMEA doc. ref. EMEA/576176/2009, Stockholm, September 2009, European Centre for Disease Prevention and Control.
4. Boman, H. G. Antibacterial peptides: basic facts and emerging concepts. J. Int. Med., 2003, 254: 197-215.
5. Hancock, R. E. W.; Patrzykat, A. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr. Drug Targets Infect. Disord., 2002, 2(1),79-83.
6. Brötz-Oesterhelt, H; Sass, P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol., 2010, 5(10),1553-79.
7. Gwynn, M.N.; Portnoy, A.; Rittenhouse, S.F.; Payne, D.J. Challenges of antibacterial discovery revisited. Ann. N. Y. Acad. Sci., 2010, 1213, 5-19.
8. Hamad, B. The antibiotics market. Nat. Rev. Drug Discov., 2010, 9(9), 675-676.
9. Jagusztyn-Krynicka, E.K.; Wyszńska, A. The decline of antibiotic era-new approaches for antibacterial drug discovery. Pol. J. Microbiol., 2008, 57, 91-98.
10. Dubois, E.A.; Cohen, A.F. Retapamulin. Br. J. Clin. Pharmacol., 2010, 69(1), 2-3.
11. Giuliani, A.; Pirri, G.; Bozzi, A.; Di Giulio, A.; Aschi, M.; Rinaldi, A.C. Antimicrobial peptides: natural templates for synthetic membrane- active compounds. Cell. Mol. Life Sci. 2008, 65(16), 2450-60.
12. Parisien, A.; Allain, B.; Zhang, J.; Mandeville, R.; Lan, C.Q. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J. Appl. Microbiol., 2008, 104(1), 1-13.
13. Escaich, S. Antivirulence as a new antibacterial approach for chemotherapy. Curr. Opin. Chem. Biol. 2008, 12(4), 400-408.
14. Bulet, P.; Stöcklin, R.; Menin, L. Anti-microbial peptides: from invertebrates to vertebrates. Immunol. Rev. 2004, 198, 169-184.
15. Jenssen, H.; Hamill, P.; Hancock, R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006, 19(3), 491-511.
16. Scott, R.W.; DeGrado, W.F.; Tew, G.N. De novo designed synthetic mimics of antimicrobial peptides. Curr. Opin. Biotechnol., 2008, 19(6), 620-627.
17. Maróti, G.; Kereszt, A.; Kondorosi, E.; Mergaert, P. Natural roles of antimicrobial peptides in microbes, plants and animals. Res. Microbiol., 2011, 162(4), 363-374.
18. Otte, J.M.; Kiehne, K.; Herzig, K.H. Antimicrobial peptides in innate immunity of the human intestine. J. Gastroenterol., 2003;38(8), 717-726.
19. Brogden, K.A.; Ackermann, M.; McCray, P.B. Jr.; Tack, B.F. Antimicrobial peptides in animals and their role in host defences. Int. J. Antimicrob. Agents, 2003, 22(5):465-478.
20. Hancock, R.E.; Scott, M.G. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(16), 8856-8861.
21. Steinstraesser, L.; Kraneburg, U.M.; Hirsch, T.; Kesting, M.; Steinau, H.U.; Jacobsen, F.; Al-Benna, S. Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int. J. Mol. Sci., 2009, 10(9), 3951-3970.
22. Wiesner, J.; Vilcinskas, A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence, 2010, 1(5), 440-64.
23. Chopra, I. The magainins: antimicrobial peptides with potential for topical application. J. Antimicrob. Chemother., 1993, 32(3), 351-353.
24. Hancock, R.E.; Patrzykat, A. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr. Drug Targets Infect. Disord., 2002, 2(1), 79-83.
25. Bommarius, B.; Kalman, D. Antimicrobial and host defense peptides for therapeutic use against multidrug-resistant pathogens: new hope on the horizon. IDrugs, 2009, 12(6), 376-380.
26. Tew, G.N.; Scott, R.W.; Klein, M.L.; Degrado, W.F. De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications. Acc. Chem. Res., 2010, 43(1), 30-39.
27. Liu, S.P.; Zhou, L.; Lakshminarayanan, R.; Beuerman, R.W. Multivalent Antimicrobial Peptides as Therapeutics: Design Principles and Structural Diversities. Int. J. Pept. Res. Ther., 2010, 16(3), 199-213.
28. Harris, F.; Dennison, S.R.; Phoenix, D.A. Anionic antimicrobial peptides from eukaryotic organisms. Curr. Protein Pept Sci., 2009, 10(6), 585-606.
29. Bowdish, D.M.; Davidson, D.J.; Hancock, R.E. Immunomodulatory properties of defensins and cathelicidins. Curr. Top. Microbiol. Immunol., 2006, 306, 27-66.
30. Mookherjee, N., Rehaume, L.M., Hancock, R.E. Cathelicidins and functional analogues as antisepsis molecules. Expert Opin. Ther. Targets, 2007, 11(8), 993-1004.
31. Hölzl, M.A.; Hofer, J.; Steinberger, P.; Pfistershammer, K.; Zlabinger, G.J. Host antimicrobial proteins as endogenous immunomodulators. Immunol. Lett., 2008, 119(1-2), 4-11.
32. Mader, J.S.; Hoskin, D.W. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin. Investig. Drugs, 2006, 15(8), 933-46.
33. Finlay, B.B.; Hancock, R.E. Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol., 2004, 2(6), 497-504
34. Oyston, P.C.; Fox, M.A.; Richards, S.J.; Clark, G.C. Novel peptide therapeutics for treatment of infections. J. Med. Microbiol., 2009, 58(Pt 8), 977-987.
35. Yoshida, H.; Kinoshita, K.; Ashida, M. Purification of a peptidoglycan recognition protein from hemolymph of the silkworm, Bombyx mori. J. Biol. Chem., 1996, 271(23), 13854-13860.
36. Kang, D.; Liu, G.; Lundström, A.; Gelius, E.; Steiner, H. A peptidoglycan recognition protein in innate immunity conserved from insects to humans. Proc. Natl. Acad. Sci. U S A. 1998, 95(17), 10078-10082.
37. Wang, G.; Li, X.; Wang, Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res., 2009, 37, D933-D937.
38. Pandey, B.K.; Ahmad, A.; Asthana, N.; Azmi, S.; Srivastava, R.M.; Srivastava, S.; Verma, R.; Vishwakarma, A.L.; Ghosh, J.K. Cellselective lysis by novel analogues of melittin against human red blood cells and Escherichia coli. Biochemistry, 2010, 49(36), 7920-7929.
39. Huang, Y.; Huang, J.; Chen, Y. Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein Cell., 2010, 1(2), 143-152.
40. Lai, X.Z.; Feng, Y.; Pollard, J.; Chin, J.N.; Rybak, M.J.; Bucki, R.; Epand, R.F.; Epand, R.M.; Savage, P.B. Ceragenins: cholic acidbased mimics of antimicrobial peptides. Acc. Chem. Res,. 2008, 41(10), 1233-1240.
41. Chin, J.N.; Rybak, M.J.; Cheung, C.M.; Savage, P.B. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob. Agents Chemother., 2007, 51, 1268-1273.
42. Gabriel, G.J.; Tew, G.N. Conformationally rigid proteomimetics: a case study in designing antimicrobial aryl oligomers. Org. Biomol. Chem., 2008, 6(3), 417-423.
43. Zhu, S. Evidence for myxobacterial origin of eukaryotic defensins. Immunogenetics, 2007, 59(12), 949-954.
44. Verma, C.; Seebah, S.; Low, S.M.; Zhou, L.; Liu, S.P.; Li, J.; Beuerman, R.W. Defensins: antimicrobial peptides for therapeutic development. Biotechnol. J., 2007, 2(11), 1353-1359.
45. Gallo, R.L.; Murakami, M.; Ohtake, T.; Zaiou, M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J. Allergy Clin. Immunol., 2002, 110(6), 823-831.
46. Pazgier, M.; Li, X.; Lu, W.; Lubkowski, J. Human defensins: synthesis and structural properties. Curr. Pharm. Des., 2007;13(30), 3096-3118.
47. Guaní-Guerra, E.; Santos-Mendoza, T.; Lugo-Reyes, S.O.; Terán, L.M. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin. Immunol., 2010, 135(1), 1-11.
48. Doss, M.; White, M.R.; Tecle, T.; Hartshorn, K.L. Human defensins and LL-37 in mucosal immunity. J. Leukoc. Biol., 2010, 87(1), 79-92.
49. Droin, N; Hendra, J.B; Ducoroy, P; Solary, E. Human defensins as cancer biomarkers and antitumour molecules. J. Proteomics, 2009, 72(6), 918-927.
50. Chen, H.; Xu, Z.; Peng, L.; Fang, X.; Yin, X.; Xu, N.; Cen, P. Recent advances in the research and development of human defensins. Peptides, 2006, 27(4), 931-940.
51. Bevins, C.L. Paneth cell defensins: key effector molecules of innate immunity. Biochem. Soc. Trans., 2006, 34(Pt 2),: 263-266.
52. Wencker, M., Brantly, M.L. Cytotoxic concentrations of alphadefensins in the lungs of individuals with alpha 1-antitrypsin deficiency and moderate to severe lung disease. Cytokine, 2005, 32(1), 1-6.
53. Kougias, P.; Chai, H.; Lin, P.H.; Yao, Q.; Lumsden, A.B.; Chen, C. Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis. J. Cell. Mol. Med., 2005, 9(1), 3-10.
54. Ramasundara, M.; Leach, S.T.; Lemberg, D.A.; Day, A.S. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J. Gastroenterol. Hepatol., 2009, 24(2), 202-208.
55. Mygind, P.H.; Fischer, R.L.; Schnorr, K.M.; Hansen, M.T.; Sönksen, C.P.; Ludvigsen, S.; Raventós, D.; Buskov, S.; Christensen, B.; De Maria, L.; Taboureau, O.; Yaver, D.; Elvig-Jørgensen, S.G.; Sørensen, M.V.; Christensen, B.E.; Kjaerulff, S.; Frimodt-Moller, N.; Lehrer, R.I.; Zasloff, M.; Kristensen, H.H. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature, 2005, 437, 975-980.
56. Schneider, T.; Kruse, T.; Wimmer, R.; Wiedemann, I.; Sass, V.; Pag, U.; Jansen, A.; Nielsen, A.K.; Mygind, P.H.; Raventós, D.S.; Neve, S.; Ravn, B.; Bonvin, A.M.; De Maria, L.; Andersen, A.S.; Gammelgaard, L.K.; Sahl, H.G.; Kristensen, H.H. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science, 2010, 328(5982), 1168-1172.
57. Brinch, K.S.; Tulkens, P.M.; Van Bambeke, F.; Frimodt-Møller, N.; Høiby, N.; Kristensen, H.H. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. J. Antimicrob. Chemother., 2010, 65(8), 1720-1724.
58. Wohlford-Lenane, C.L.; Meyerholz, D.K.; Perlman, S.; Zhou, H.; Tran, D.; Selsted, M.E.; McCray, P.B. Jr. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J. Virol., 2009, 83(21), 11385-11390.
59. Venkataraman, N.; Cole, A.L.; Ruchala, P.; Waring, A.J.; Lehrer, RI.; Stuchlik, O.; Pohl, J.; Cole, A.M. Reawakening retrocyclins: ancestral human defensins active against HIV-1: PLoS Biol., 2009, 7(4), e95.
60. Wang, W.; Owen, S.M.; Rudolph, D.L.; Cole, A.M.; Hong, T.; Waring, A.J.; Lal, R.B.; Lehrer, R.I. Activity of alpha- and thetadefensins against primary isolates of HIV-1. J. Immunol., 2004, 173(1), 515-520.
61. Liang, Q.L.; Zhou, K.; He, H.X. Retrocyclin 2: a new therapy against avian influenza H5N1 virus in vivo and vitro. Biotechnol. Lett., 2010, 32(3), 387-392.
62. Lee, S.B.; Li, B.; Jin, S.; Daniell, H. Expression and characterization of antimicrobial peptides Retrocyclin-101 and Protegrin-1 in chloroplasts to control viral and bacterial infections. Plant Biotechnol. J., 2011, 9(1), 100-115.
63. Zhu, S. Did cathelicidins, a family of multifunctional host-defense peptides, arise from a cysteine protease inhibitor? Trends Microbiol. 2008, 16(8), 353-360.
64. Zanetti, M. The role of cathelicidins in the innate host defenses of mammals. Curr. Issues Mol. Biol., 2005, 7(2), 179-196.
65. White, J.H. Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: past, present and future. J. Steroid Biochem. Mol. Biol., 2010, 121(1-2), 234-8.
66. Scott, M.G.; Davidson, D.J.; Gold, M.R.; Bowdish, D.; Hancock, R.E. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol., 2002, 169(7), 3883-3891.
67. Méndez-Samperio, P. The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections. Peptides, 2010, 31(9), 1791-1798.
68. Rivas-Santiago, B.; Hernandez-Pando, R.; Carranza, C.; Juarez, E.; Contreras, J.L.; Aguilar-Leon, D.; Torres, M.; Sada, E. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect. Immun., 2008, 76(3), 935-941.
69. Ciornei, C.D.; Sigurdardóttir, T.; Schmidtchen, A.; Bodelsson, M. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob. Agents Chemother., 2005, 49(7), 2845-2850.
70. Bucki, R.; Leszczyńska, K.; Namiot, A.; Sokoiowski, W. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch. Immunol. Ther. Exp., 2010, 58(1), 15-25.
71. Mookherjee, N.; Hancock, R.E. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell. Mol. Life Sci., 2007, 64(7-8), 922-933.
72. Scott, M.G.; Dullaghan, E.; Mookherjee, N.; Glavas, N.; Waldbrook, M.; Thompson, A.; Wang, A.; Lee, K.; Doria, S.; Hamill, P.; Yu, J.J.; Li, Y., Donini, O.; Guarna, M.M.; Finlay, B.B.; North, J.R.; Hancock, R.E. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol., 2007, 25(4), 465-472.
73. Nijnik, A.; Madera, L.; Ma, S.; Waldbrook, M.; Elliott, M.R.; Easton, D.M.; Mayer, M.L.; Mullaly, S.C.; Kindrachuk, J.; Jenssen, H.; Hancock, R.E. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J. Immunol., 2010, 184(5), 2539-2550.
74. Dorosz, J.; Gofman, Y.; Kolusheva, S.; Otzen, D.; Ben-Tal, N.; Nielsen, N.C.; Jelinek, R. Membrane interactions of novicidin, a novel antimicrobial peptide: phosphatidylglycerol promotes bilayer insertion. J. Phys. Chem. B., 2010, 114(34), 11053-11060.
75. Zhang, Y.; Zhao, H.; Yu, G.Y.; Liu, X.D.; Shen, J.H.; Lee, W.H.; Zhang Y. Structure-function relationship of king cobra cathelicidin. Peptides, 2010, 31(8), 1488-1493.
76. Hultmark, D.; Steiner, H.; Rasmuson, T.; Boman, H.G. Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur. J. Biochem. 1980, 106(1), 7-16.
77. Bechinger, B.; Lohner, K. Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim. Biophys. Acta, 2006, 1758(9), 1529-1539.
78. Chen, X.; Jorgenson, E.; Cheung, S.T. New tools for functional genomic analysis. Drug Discov. Today, 2009, 14(15-16), 754-760.
79. Wu, J.M.; Jan, P.S.; Yu, H.C.; Haung, H.Y.; Fang, H.J.; Chang, Y.I.; Cheng, J.W.; Chen, H.M. Structure and function of a custom anticancer peptide, CB1a. Peptides, 2009, 30(5), 839-848.
80. Plunkett, R.M.; Murray, S.I.; Lowenberger, C.A. Generation and characterization of the antibacterial activity of a novel hybrid antimicrobial peptide comprising functional domains from different insect cecropins. Can. J. Microbiol., 2009, 55(5), 520-528.
81. Lu, X.M.; Jin, X.B.; Zhu, J.Y.; Mei, H.F.; Ma, Y.; Chu, F.J.; Wang, Y.; Li, X.B. Expression of the antimicrobial peptide cecropin fused with human lysozyme in Escherichia coli. Appl. Microbiol. Biotechnol., 2010, 87(6), 2169-2176.
82. Chen, X.; Zhu, F.; Cao, Y.; Qiao, S. Novel expression vector for secretion of cecropin AD in Bacillus subtilis with enhanced antimicrobial activity. Antimicrob. Agents Chemother., 2009, 53(9), 3683-9.
83. Cao, Y.; Yu, R.Q.; Liu, Y.; Zhou, H.X.; Song, L.L.; Cao, Y.; Qiao, D.R. Design, recombinant expression, and antibacterial activity of the cecropins-melittin hybrid antimicrobial peptides. Curr. Microbiol., 2010, 61(3), 169-175.
84. Rodríguez-Hernández, M.J.; Saugar, J.; Docobo-Pérez, F.; de la Torre, B.G.; Pachón-Ibáñez, M.E.; García-Curiel, A.; Fernández- Cuenca, F.; Andreu D.; Rivas, L.; Pachón, J. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistinresistant clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother., 2006, 58(1), 95-100.
85. López-Rojas, R.; Docobo-Pérez, F.; Pachón-Ibáñez, M.E.; de la Torre, B.G.; Fernández-Reyes, M.; March, C.; Bengoechea, J.A.; Andreu, D.; Rivas, L.; Pachón, J. Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii. Eur. J. Clin. Microbiol. Infect. Dis., 2011, Apr 12. [Epub ahead of print]
86. Zairi, A.; Tangy, F.; Bouassida, K.; Hani, K. Dermaseptins and magainins: antimicrobial peptides from frogs' skin-new sources for a promising spermicides microbicides-a mini review. J. Biomed. Biotechnol. 2009, 2009, 452567.
87. Zasloff, M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. U S A., 1987, 84(15), 5449-5453.
88. Clara, A.; Manjramkar, D.D.; Reddy, V.K. Preclinical evaluation of magainin-A as a contraceptive antimicrobial agent. Fertil. Steril. 2004, 81(5), 1357-1365.
89. Gottler, L.M.; Ramamoorthy, A. Structure, membrane orientation, mechanism, and function of pexiganan- a highly potent antimicrobial peptide designed from magainin. Biochim. Biophys. Acta, 2009, 1788(8), 1680-1686.
90. Lohner, K.; Prossnigg, F. Biological activity and structural aspects of PGLa interaction with membrane mimetic systems. Biochim. Biophys. Acta, 2009, 1788(8), 1656-1666.
91. Zairi, A., Tangy, F., Ducos-Galand, M., Alonso, J.M., Hani, K. Susceptibility of Neisseria gonorrhoeae to antimicrobial peptides from amphibian skin, dermaseptin, and derivatives. Diagn. Microbiol. Infect. Dis., 2007, 57(3), 319-324.
92. Savoia, D.; Guerrini, R.; Marzola, E.; Salvadori, S. Synthesis and antimicrobial activity of dermaseptin S1 analogues. Bioorg. Med. Chem., 2008, 16(17), 8205-8209.
93. Savoia, D.; Donalisio, M.; Civra, A.; Salvadori, S.; Guerrini, R. In vitro activity of dermaseptin S1 derivatives against genital pathogens. APMIS, 2010, 118(9), 674-680.
94. Yasuhara, T.; Nakajima, T.; Erspamer, V.; Falconieri Erspamer, G.; Tukamoto, Y.; Mori, M. In: Peptide chemistry; Kiso, Y. Ed.; Protein Research Foundation: Osaka, 1986; pp. 363-368
95. Simmaco, M.; Mignogna, G.; Canofeni, S.; Miele, R.; Mangoni, M.L.; Barra, D. Temporins, antimicrobial peptides from the European red frog Rana temporaria. Eur. J. Biochem., 1996, 242(3), 788-792.
96. Mahalka, A.K.; Kinnunen, P.K. Binding of amphipathic alphahelical antimicrobial peptides to lipid membranes: lessons from temporins B and L. Biochim, Biophys, Acta, 2009, 1788(8), 1600-1609.
97. Mangoni, M.L.; Carotenuto, A.; Auriemma, L.; Saviello, M.R.; Campiglia, P.; Gomez-Monterrey, I.; Malfi, S.; Marcellini, L.; Barra, D.; Novellino, E.; Grieco, P. Structure-activity relationship, conformational and biological studies of temporin L analogues. J. Med. Chem., 2011, 54(5), 1298-307.
98. Mangoni, M.L.; Shai, Y. Temporins and their synergism against Gram-negative bacteria and in lipopolysaccharide detoxification. Biochim. Biophys. Acta, 2009, 1788(8):1610-1619.
99. Duquesne, S.; Petit, V.; Peduzzi, J.; Rebuffat, S. Structural and functional diversity of microcins, gene-encoded antibacterial peptides from enterobacteria. J. Mol. Microbiol. Biotechnol., 2007, 13(4), 200-209.
100. Destoumieux-Garzón, D.; Peduzzi, J.; Rebuffat, S. Focus on modified microcins: structural features and mechanisms of action. Biochimie, 2002, 84(5-6), 511-519.
101. Corsini, G.; Karahanian, E.; Tello, M.; Fernandez, K.; Rivero, D.; Saavedra, J.M.; Ferrer, A. Purification and characterization of the antimicrobial peptide microcin N. FEMS Microbiol. Lett., 2010, 312(2), 119-125.
102. Lagos, R.; Tello, M.; Mercado, G.; García, V.; Monasterio, O. Antibacterial and antitumorigenic properties of microcin E492, a pore-forming bacteriocin. Curr. Pharm. Biotechnol., 2009, 10(1), 74-85.
103. Oman, T.J.; van der Donk, W.A. Follow the leader: the use of leader peptides to guide natural product biosynthesis. Nat. Chem. Biol., 2010, 6(1), 9-18.
104. Sit, C.S.; Vederas, J.C. Approaches to the discovery of new antibacterial agents based on bacteriocins. Biochem. Cell. Biol., 2008, 86(2), 116-23.
105. Cotter, P.D.; Hill, C.; Ross, R.P. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol., 2005, 3(10), 777-88.
106. Chatterjee, C.; Paul, M.; Xie, L.; van der Donk, W.A. Biosynthesis and mode of action of lantibiotics. Chem. Rev., 2005, 105(2), 633-684.
107. Ross, A.C.; Vederas, J.C. Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. J. Antibiot., 2011, 64(1), 27-34.
108. Cotter, P.D.; Hill, C.; Ross, R.P. Bacterial lantibiotics: strategies to improve therapeutic potential. Curr. Protein Pept. Sci., 2005, 6(1), 61-75.
109. Turpin, E.R.; Bonev, B.B.; Hirst, J.D. Stereoselective disulfide formation stabilizes the local peptide conformation in nisin mimics. Biochemistry, 2010, 49(44), 9594-603
110. Gut, I.M.; Blanke, S.R.; van der Donk, W.A. Mechanism of Inhibition of Bacillus anthracis Spore Outgrowth by the Lantibiotic Nisin. ACS Chem. Biol., 2011, April 26, E pub ahead pf print.
111. Rollema, H.S.; Kuipers, O.P.; Both, P.; de Vos, W.M.; Siezen, R.J. Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl. Environ. Microbiol., 1995, 61(8), 2873-2878.
112. Carroll J, Field D, O'Connor PM, Cotter PD, Coffey A, Hill C, Ross RP, O'Mahony J. Gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. Bioeng. Bugs, 2010, 1(6), 408-412.
113. Piper, C.; Draper, L.A.; Cotter, P.D.; Ross, R.P.; Hill, C. A comparison of the activities of lacticin 3147 and nisin against drugresistant Staphylococcus aureus and Enterococcus species. J. Antimicrob. Chemother., 2009, 64(3), 546-551.
114. Rea, M.C.; Sit, C.S.; Clayton, E.; O'Connor, P.M.; Whittal, R.M.; Zheng, J.; Vederas, J.C.; Ross, R.P.; Hill, C. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc. Natl. Acad. Sci. U S A., 2010, 107(20), 9352-9357.
115. Nissen-Meyer, J.; Oppegård, C.; Rogne, P.; Haugen, H.S.; Kristiansen, P.E. Structure and Mode-of-Action of the Two-Peptide (Class-IIb) Bacteriocins. Probiotics Antimicrob. Proteins, 2010, 2(1), 52-60.
116. Kjos, M.; Nes, I.F.; Diep, D.B. Mechanisms of resistance to bacteriocins targeting the mannose phosphotransferase system. Appl. Environ. Microbiol., 2011, 77(10), 3335-3342.
117. Bera, A.; Singh, S.; Nagaraj, R.; Vaidya, T. Induction of autophagic cell death in Leishmania donovani by antimicrobial peptides. Mol. Biochem. Parasitol., 2003, 127(1), 23-35.
118. Rokitskaya, T.I.; Kolodkin, N.I.; Kotova, E.A.; Antonenko, Y.N. Indolicidin action on membrane permeability: Carrier mechanism versus pore formation. Biochim. Biophys. Acta, 2011, 1808(1), 91-97.
119. Rubinchik, E.; Dugourd, D.; Algara, T.; Pasetka, C.; Friedland, H.D. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int. J. Antimicrob. Agents, 2009, 34(5), 457-461.
120. Lee, S.H.; Kim, S.J.; Lee, Y.S.; Song, M.D.; Kim, I.H.; Won, H.S. De novo generation of short antimicrobial peptides with simple amino acid composition. Regul. Pept., 2010, Aug 22. [Epub ahead of print].
121. Zhanel, G.G.; Calic, D.; Schweizer, F.; Zelenitsky, S.; Adam, H.; Lagacé-Wiens, P.R.; Rubinstein, E.; Gin, A.S.; Hoban, D.J.; Karlowsky, J.A. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs, 2010, 70(7), 859-886.
122. Welte, T.; Pletz, M.W. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int. J. Antimicrob. Agents, 2010, 36(5), 391-400.
123. Belley, A.; McKay, G.A.; Arhin, F.F.; Sarmiento, I.; Beaulieu, S.; Fadhil, I.; Parr, T.R. Jr.; Moeck, G. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob. Agents Chemother., 2010, 54(12), 5369-5371.
124. Barczak, A.K.; Hung, D.T. Productive steps toward an antimicrobial targeting virulence. Curr. Opin. Microbiol., 2009, 12(5), 490-496.
125. Aberg, V.; Almqvist, F. Pilicides-small molecules targeting bacterial virulence. Org. Biomol. Chem., 2007, 5(12), 1827-1834.
126. Nielsen, A.; Nielsen, K.F.; Frees, D.; Larsen, T.O.; Ingmer, H. Method for screening compounds that influence virulence gene expression in Staphylococcus aureus. Antimicrob. Agents Chemother., 2010, 54(1), 509-512.
127. Clatworthy, A.E.; Pierson, E.; Hung, D.T. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol., 2007, 3(9), 541-548.
128. Johnson, J.R. Virulence factors in Escherichia coli urinary tract infection Clin. Microbiol. Rev., 1991, 4(1), 80-128.
129. Nobbs, A.H.; Lamont, R.J.; Jenkinson, H.F. Streptococcus adherence and colonization. Microbiol. Mol. Biol. Rev., 2009, 73(3), 407-450.
130. Chenna, B.C.; Shinkre, B.A.; King, J.R.; Lucius, A.L.; Narayana, S.V.; Velu, S.E. Identification of novel inhibitors of bacterial surface enzyme Staphylococcus aureus Sortase A. Bioorg. Med. Chem. Lett., 2008, 18(1), 380-385.
131. Suree, N.; Yi, S.W.; Thieu, W.; Marohn, M.; Damoiseaux, R.; Chan, A.; Jung, M.E.; Clubb, R.T. Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorg. Med. Chem., 2009, 17(20), 7174-7185.
132. Carbonnelle, E.; Hill, D.J.; Morand, P.; Griffiths, N.J.; Bourdoulous, S.; Murillo, I.; Nassif, X.; Virji, M. Meningococcal interactions with the host. Vaccine, 2009, 27 Suppl 2, B78-B89.
133. Barnhart, M.M.; Chapman, M.R. Curli biogenesis and function. Annu. Rev. Microbiol., 2006, 60, 131-147.
134. Kikuchi, T.; Mizunoe, Y.; Takade, A.; Naito, S.; Yoshida, S. Curli fibers are required for development of biofilm architecture in Escherichia coli K-12 and enhance bacterial adherence to human uroepithelial cells. Microbiol. Immunol., 2005, 49(9), 875-884.
135. Cegelski, L.; Pinkner, J.S.; Hammer, N.D.; Cusumano, C.K.; Hung, C.S.; Chorell, E.; Aberg, V.; Walker, J.N.; Seed, P.C.; Almqvist, F.; Chapman M.R.; Hultgren, S.J. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Na. Chem. Biol., 2009, 5(12), 913-919.
136. Touaibia, M.; Roy, R. Glycodendrimers as anti-adhesion drugs against type 1 fimbriated E. coli uropathogenic infections. Mini Rev. Med. Chem., 2007, 7(12), 1270-1283.
137. Høiby, N.; Ciofu, O.; Johansen, H.K.; Song, Z.J.; Moser, C.; Jensen, P.Ø.; Molin, S.; Givskov, M.; Tolker-Nielsen, T.; Bjarnsholt, T. The clinical impact of bacterial biofilms. Int. J. Oral Sci., 2011, 3(2), 55-65.
138. Martin, C.A.; Hoven, A.D.; Cook, A.M. Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing. Eur. J. Clin. Microbiol. Infect. Dis., 2008, 27(8), 635-642.
139. Pan, J.; Ren, D. Quorum sensing inhibitors: a patent overview. Expert Opin. Ther. Pat., 2009, 19(11), 1581-1601.
140. Costerton, J.W.; Montanaro, L.; Arciola, C.R. Bacterial communications in implant infections: a target for an intelligence war. Int. J. Artif. Organs, 2007, 30(9), 757-763.
141. Shank, E.A.; Kolter, R. New developments in microbial interspecies signaling. Curr. Opin. Microbiol., 2009, 12(2), 205-214.
142. Sintim, H.O.; Smith, J.A.; Wang, J.; Nakayama, S.; Yan, L. Paradigm shift in discovering next-generation anti-infective agents: targeting quorum sensing, c-di-GMP signaling and biofilm formation in bacteria with small molecules. Future Med. Chem., 2010, 2(6), 1005-1035.
143. Mitchell, R.J.; Lee, S.K.; Kim, T., Ghim, C.M. Microbial linguistics: perspectives and applications of microbial cell-to-cell communication. BMB Rep., 2011, 44(1), 1-10.
144. Lazar, V. Quorum sensing in biofilms - How to destroy the bacterial citadels or their cohesion/power? Anaerobe, 2011, Apr 8. Epub ahead of print.
145. Goryachev, A.B. Understanding bacterial cell-cell communication with computational modeling. Chem. Rev., 2011, 111(1), 238-250.
146. Stevens, A.M.; Queneau, Y.; Soulère, L.; von Bodman, S.; Doutheau, A. Mechanisms and synthetic modulators of AHLdependent gene regulation. Chem. Rev., 2011, 111(1), 4-27.
147. Hung, D.T.; Shakhnovich, E.A.; Pierson, E.; Mekalanos, J.J. Smallmolecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science, 2005, 310(5748), 670-674.
148. Puri, A.W.; Lupardus, P.J.; Deu, E.; Albrow, V.E.; Garcia, K.C.; Bogyo, M.; Shen, A. Rational design of inhibitors and activitybased probes targeting Clostridium difficile virulence factor TcdB. Chem. Biol., 2010, 17(11), 1201-1211.
149. Critchley, I.A.; Ochsner, U.A. Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839. Curr. Opin. Chem. Biol., 2008, 12(4), 409-417.
150. Ochsner, U.A.; Bell, S.J.; O'Leary, A.L.; Hoang, T.; Stone, K.C.; Young, C.L.; Critchley, I.A.; Janjic, N. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J. Antimicrob. Chemother., 2009, 63(5), 964-971.
151. Shoop, W.L.; Xiong, Y.; Wiltsie, J.; Woods, A.; Guo, J.; Pivnichny, J.V.; Felcetto, T.; Michael, B.F.; Bansal, A.; Cummings, R.T.; Cunningham, B.R.; Friedlander, A.M.; Douglas, C.M.; Patel, S.B.; Wisniewski, D.; Scapin, G.; Salowe, S.P.; Zaller, D.M.; Chapman, K.T.; Scolnick, E.M.; Schmatz, D.M.; Bartizal, K.; MacCoss, M.; Hermes, J.D. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. U S A., 2005, 102(22), 7958-7963.
152. Agrawal, A.; de Oliveira, C.A.; Cheng, Y.; Jacobsen, J.A.; McCammon, J.A.; Cohen, S.M. Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor. J. Med. Chem., 2009, 52(4), 1063-1074.
153. d'Herelle, F. Le Bactériophage et ses Applications Thérapeutiques. Doin: Paris, 1933.
154. Verma, V.; Harjai, K.; Chhibber, S. Characterization of a T7-like lytic bacteriophage of Klebsiella pneumoniae B5055: a potential therapeutic agent. Curr. Microbiol., 2009, 59(3), 274-281.
155. Harper, D.R.; Enright, M.C. Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J. Appl. Microbiol., 2011, Mar 16. Epub ahead of print.
156. Housby, J.N.; Mann, N.H. Phage therapy. Drug Discov. Today, 2009, 14(11-12), 536-540.
157. Fu, W.; Forster, T.; Mayer, O.; Curtin, J.J.; Lehman, S.M.; Donlan, R.M. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob. Agents Chemother., 2010, 54(1), 397-404.
158. Payne, R.J.; Jansen, V.A. Pharmacokinetic principles of bacteriophage therapy. Clin. Pharmacokinet., 2003, 42(4), 315-325.
159. Morello, E.; Saussereau, E.; Maura, D.; Huerre, M.; Touqui, L.; Debarbieux, L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One, 2011, 6(2), e16963.
160. Wright, A.; Hawkins, C.H.; Anggård, E.E.; Harper, D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol., 2009, 34(4), 349-357.
161. Borysowski, J.; Weber-Dabrowska, B.; Górski, A. Bacteriophage endolysins as a novel class of antibacterial agents. Exp. Biol. Med., 2006, 231(4), 366-377.
162. Briers, Y.; Walmagh, M.; Lavigne, R. Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J. Appl. Microbiol., 2011, 110(3), 778-785.
163. Fischetti, V.A. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int. J. Med. Microbiol., 2010, 300(6), 357-362.
164. Schuch, R.; Nelson, D.; Fischetti, V.A. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature, 2002, 418(6900), 884-889.
165. Jado, I.; López, R.; García, E.; Fenoll, A.; Casal, J.; García, P. Spanish Pneumococcal Infection Study Network. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother., 2003, 52(6), 967-973.
166. Cheng, Q.; Nelson, D.; Zhu, S.; Fischetti, V.A. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother., 2005, 49(1), 111-117.
167. Loeffler, J.M.; Nelson, D.; Fischetti, V.A. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science, 2001, 294(5549), 2170-2172.
168. Fischetti, V.A. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol., 2008, 11(5), 393-400.
169. Witzenrath, M.; Schmeck, B.; Doehn, J.M.; Tschernig, T.; Zahlten, J.; Loeffler, J.M.; Zemlin, M.; Müller, H.; Gutbier, B.; Schütte, H.; Hippenstiel, S.; Fischetti, V.A.; Suttorp, N.; Rosseau, S. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit. Care Med., 2009, 37(2), 642-649.
170. Davies, J. How to discover new antibiotics: harvesting the parvome. Curr. Opin. Chem. Biol., 2011, 15(1), 5-10.
171. Oh, D.; Shin, S.Y.; Kang, J.H.; Hahm, K.S.; Kim, K.L.; Kim, Y. NMR structural characterization of cecropin A(1-8) - magainin 2(1- 12) and cecropin A (1-8) - melittin (1-12) hybrid peptides. J. Pept. Res., 1999, 53(5), 578-589.
172. Bayro, M.J.; Mukhopadhyay, J.; Swapna, G.V.; Huang, J.Y.; Ma, L.C.; Sineva, E.; Dawson, P.E.; Montelione, G.T.; Ebright, R.H. Structure of antibacterial peptide microcin J25: a 21-residue lariat protoknot. J. Am. Chem. Soc., 2003, 125(41), 12382-12383.
173. Wang, G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J. Biol. Chem., 2008, 283(47), 32637-32643.
174. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res., 2000, 28(1), 235-242.